Most Recent
Lender White Oak may argue that settlement communications in proceedings over the collapse of supply chain finance company Greensill were in furtherance of fraud and should be turned over, after partially succeeding in a privilege fight with insurers BCC Trade Credit and Tokio Marine.
A former RAMS franchisee has raised concerns about a joint trial of its case with a related class action against the defunct Westpac home loan subsidiary, saying the overlap between the cases may be “much less than advertised”.
Construction PRO
A court has found that a minister's decision to sell a section of Crown land to a buyer intending to carve it into 15 lots was made in breach of planning laws.
Class action settlements hit major milestones last year, with the year’s largest settlements totalling $1.6 billion and one case resolving for a historic $548.5 million.
The Takeovers Panel has found Cosette cannot close a Mayne Pharma drug manufacturing plant in Adelaide, another win for Mayne in its push to block the US drug maker from walking away from their $672 million merger.
The Foreign Investment Review Board has extended the deadline for ruling on Cosette's proposed $672 million takeover of Mayne Pharma.
The Takeovers Panel has agreed to hear Mayne Pharma's latest dispute with Cosette over the US drug maker's attempts to walk away from their $672 million merger agreement and extended the timeline for completing the deal.
Mayne Pharma has secured an extension of the deadline for securing Foreign Investment Review Board approval of its $672 million tie-up with US drug maker Cosette.
Cosette plans to appeal a ruling that rejected its bid to terminate an agreement to merge with Mayne Pharma, as the US drug company also refuses to agree to conditions needed to win Foreign Investment Review Board approval for the tie-up.
Mayne Pharma has won a dispute with US drug maker Cosette over the termination of a $672 million merger agreement, with a judge finding Mayne did not breach its continuous disclosure obligations by failing to disclose a letter from the US FDA sooner.